Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.

Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE; ACCELERATE Investigators.

N Engl J Med. 2017 May 18;376(20):1933-1942. doi: 10.1056/NEJMoa1609581.

PMID:
28514624
2.

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.

Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators.

N Engl J Med. 2017 Apr 20;376(16):1527-1539. doi: 10.1056/NEJMoa1701488. Epub 2017 Mar 17.

PMID:
28304242
3.

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators.

N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.

PMID:
28304224
4.

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators.

N Engl J Med. 2016 Nov 10;375(19):1834-1844. Epub 2016 Sep 15.

5.

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group.

N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892.

6.

Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.

Punthakee Z, Bosch J, Dagenais G, Diaz R, Holman R, Probstfield J, Ramachandran A, Riddle M, Rydén LE, Zinman B, Afzal R, Yusuf S, Gerstein H; TIDE Trial Investigators.

Diabetologia. 2012 Jan;55(1):36-45. doi: 10.1007/s00125-011-2357-4. Epub 2011 Oct 29.

PMID:
22038523
7.

Impact of waist circumference reduction on cardiovascular risk in treated obese subjects.

Fanghänel G, Sánchez-Reyes L, Félix-García L, Violante-Ortiz R, Campos-Franco E, Alcocer LA.

Cir Cir. 2011 Mar-Apr;79(2):175-81.

PMID:
21631979
8.

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.

Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B; LEAD-3 (Mono) Study Group.

Diabetes Obes Metab. 2011 Apr;13(4):348-56. doi: 10.1111/j.1463-1326.2010.01356.x.

9.

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.

Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, Garber A; LEAD-3 Study Group.

Diabetes Obes Metab. 2010 Jul;12(7):604-12. doi: 10.1111/j.1463-1326.2010.01196.x.

10.

[Global problems of local impact in health].

de la Fuente JR, Silink M, Violante-Ortiz R, Alcocer L, Mazanec MB, Bond DM, Shackelton LA, Salazar-Lezama MA, Coyote-Estrada N, Betancourt-Cravioto M.

Gac Med Mex. 2009 Jul-Aug;145(4):289-321. Spanish. No abstract available.

PMID:
20073431
11.

Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.

González-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R, Wacher-Rodarte N, Martínez-Abundis E, Aguilar-Salinas C, Islas-Andrade S, Arechavaleta-Granell R, González-Canudas J, Rodríguez-Morán M, Zavala-Suárez E, Ramos-Zavala MG, Metha R, Revilla-Monsalve C, Beltrán-Jaramillo TJ.

J Diabetes Complications. 2009 Nov-Dec;23(6):376-9. doi: 10.1016/j.jdiacomp.2008.09.002. Epub 2008 Oct 11.

PMID:
18849173
12.

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B; LEAD-3 (Mono) Study Group.

Lancet. 2009 Feb 7;373(9662):473-81. doi: 10.1016/S0140-6736(08)61246-5. Epub 2008 Sep 24.

PMID:
18819705
13.

Obesity and metabolic risks in children.

Del-Rio-Navarro BE, Velazquez-Monroy O, Lara-Esqueda A, Violante-Ortiz R, Fanghanel G, Perez-Sanchez L, Berber A.

Arch Med Res. 2008 Feb;39(2):215-21. doi: 10.1016/j.arcmed.2007.07.008. Epub 2007 Oct 31.

PMID:
18164967
14.

Mexican anthropometric percentiles for ages 10-18.

Del-Rio-Navarro BE, Velazquez-Monroy O, Santos-Preciado JI, Lara-Esqueda A, Berber A, Loredo-Abdala A, Violante-Ortiz R, Tapia-Conyer R.

Eur J Clin Nutr. 2007 Aug;61(8):963-75. Epub 2007 Jan 17.

PMID:
17228343
15.

Use of sibutramine in obese Hispanic adolescents.

Violante-Ortìz R, Del-Rio-Navarro BE, Lara-Esqueda A, Pèrez P, Fanghänel G, Madero A, Berber A.

Adv Ther. 2005 Nov-Dec;22(6):642-9.

PMID:
16510381

Supplemental Content

Loading ...
Support Center